Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 615201 | CLEFMA | 1246964-32-8 | 98% Min. |  |
| CLEFMA has anti-proliferative activity in H441 cells. CLEFMA may induce autophagic ce | ||||
| 2062004 | ((1R,2S)-2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl)methyl acetate | 1369768-29-5 | ≧95.0% | -2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl)methyl_acetate_1369768-29-5.gif) |
| 262324 | 2-(3-Fluoro-4-isopropoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane | 1350426-06-0 | 98% Min. | -4,4,5,5-tetramethyl-1,3,2-dioxaborolane_1350426-06-0.png) |
| 20732 | Lanraplenib | 1800046-95-0 | 98% |  |
| Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor in develo | ||||
| 52004 | Belnacasan | 273404-37-8 | 98% | _273404-37-8.png) |
| Belnacasan is a prodrug ofVRT-043198, a caspase-1 inhibitor that was developed by Ver | ||||
| 2071401 | Pimodivir ( VX-787 ) | 1629869-44-8 | 98% Min. |  |
| Pimodivir, also known as VX-787, JNJ-872, is a novel inhibitor of influenza virus rep | ||||
| 2073107 | Trilaciclib hydrochloride (G1T28 hydrochloride) | 1977495-97-8 | 98% Min. | .png) |
| TRILACICLIB (G1T28), A HIGHLY POTENT, TRANSIENT CDK 4/6 INHIBITOR WITHIC50s OF 1 nM A | ||||
| 2073108 | PF-06802861 ( ARRY 371797 ; ARRY-797 ) | 1034189-82-6 | ≧98.0% | _1034189-82-6.png) |
| ARRY 797 (also known as ARRY 371797 or PF 06802861) is an orally active, selective p3 | ||||
| 208191 | OATD-01 (GLPG-4716) | 2088453-21-6 | ≧98.0% |  |
| OATD-01 (GLPG-4716), a dual inhibitor of acidic mammalian chitinase (AMCase) and chit | ||||
| 2091501 | AB-680 | 2105904-82-1 | 98% Min. |  |
| AB-680 is highly potent, reversible and selective CD73 inhibitor. AB680 to be a rever | ||||
| 2091502 | 5-(chloromethyl)-1-propyl-1H-imidazole hydrochloride | 497223-15-1 | ≧95.0% | -1-propyl-1H-imidazole_hydrochloride_497223-15-1.png) |
| 5-(chloromethyl)-1-propyl-1H-imidazole hydrochloride is an important intermediate of | ||||
| 20103001 | ASN007 | 2055597-12-9 | ≧98.0% |  |
| ASN007 , a novel oral ERK inhibitor , has shown anti-tumor activity in both solid tum | ||||